Effect of atracurium, vecuronium, pancuronium and tubocurarine on renal sympathetic nerve activity in baroreceptor denervated dogs.

The mechanism of arterial hypotension induced by non-depolarizing neuromuscular blocking agents may be multifactorial and differ between drugs. The purpose of this study was to evaluate the effect of high-dose atracurium and equivalent doses of other non-depolarizing neuromuscular blocking agents on haemodynamic state and sympathetic nervous activity. In studies on 24 mongrel dogs anaesthetized with alpha-chloralose, the left kidney was exposed retroperitoneally and renal sympathetic nerve activity was recorded continuously after bilateral sino-aortic denervation and cervical vagi section. The dogs were allocated to four groups; atracurium 1.5 mg kg-1, tubocurarine 0.3 mg kg-1, pancuronium 0.3 mg kg-1 or vecuronium 0.3 mg kg-1 was administered to six dogs in each group. Histamine 1 micrograms kg-1 was given to two dogs in each group, 1 h before administration of neuromuscular blocking agents. We observed that atracurium and tubocurarine significantly decreased arterial pressure, heart rate and renal sympathetic nerve activity (P < 0.05), but pancuronium and vecuronium did not Histamine-induced arterial hypotension but did not affect heart rate or renal sympathetic nerve activity. As both arterial and cardiopulmonary baroreflex pathways were inactivated in these animals, we conclude that atracurium decreased arterial pressure by suppressing efferent sympathetic nerve activity in a manner similar to that of tubocurarine.

[1]  C. Taneyama,et al.  Attenuation of arterial baroreceptor reflex response to acute hypovolemia during induced hypotension. , 1990, Anesthesiology.

[2]  G. Gronert,et al.  Combined H1 and H2 receptor blockade attenuates the cardiovascular effects of high-dose atracurium for rapid sequence endotracheal intubation. , 1988 .

[3]  R. Lennon,et al.  Combined H1 and H2 Receptor Blockade Attenuates the Cardiovascular Effects of High‐Dose Atracurium for Rapid Sequence Endotracheal Intubation , 1988, Anesthesia and analgesia.

[4]  G. Gronert,et al.  Atracurium or Vecuronium for Rapid Sequence Endotracheal Intubation , 1987 .

[5]  H. H. Ali,et al.  Clinical pharmacology of atracurium given in high dose. , 1987, British journal of anaesthesia.

[6]  H. H. Ali,et al.  Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response. , 1985, British journal of anaesthesia.

[7]  Mike Sinclair,et al.  Bradycardia after the use of atracurium , 1983, British medical journal.

[8]  H. H. Ali,et al.  Clinical Pharmacology of Atracurium Besylate (BW 33A): A New Non‐depolarizing Muscle Relaxant , 1982, Anesthesia and analgesia.

[9]  R. Hughes,et al.  The pharmacology of atracurium: a new competitive neuromuscular blocking agent. , 1981, British journal of anaesthesia.

[10]  R. Miller,et al.  Cardiovascular and Neuromuscular Effects of Org NC 45, Pancuronium, Metocurine, and d‐Tubocurarine in Dogs , 1980, Anesthesia and analgesia.

[11]  J. Savarese The Autonomic Margins of Safety of Metocurine and d‐Tubocurarine in the Cat , 1979, Anesthesiology.

[12]  R. Hughes,et al.  Cardiovascular and neuromuscular effects of dimethyl tubocurarine in anaesthetized cats and rhesus monkeys. , 1976, British journal of anaesthesia.

[13]  R. Hughes,et al.  Effects on non-depolarizing neuromuscular blocking agents on peripheral autonomic mechanisms in cats. , 1976, British journal of anaesthesia.

[14]  E. Eger,et al.  Pancuronium-induced tachycardia in relation to alveolar halothane, dose of pancuronium, and prior atropine. , 1975, Anesthesiology.